Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 370 Lymphoma, Non-Hodgkin 348 Leukemia, Lymphocytic, Chronic, B-Cell 322 Precursor Cell Lymphoblastic Leukemia-Lymphoma 291 Lymphoma, Large B-Cell, Diffuse 244 Lymphoma, Follicular 236 Leukemia 198 Hodgkin Disease 171 Lymphoma, Mantle-Cell 164 Leukemia, Myeloid, Acute 160 Multiple Myeloma 134 Myelodysplastic Syndromes 130 Recurrence 125 Burkitt Lymphoma 123 Lymphoma, B-Cell, Marginal Zone 120 Lymphoma, T-Cell, Cutaneous 92 Neoplasms 82 Mycosis Fungoides 82 Lymphoma, B-Cell 82 Waldenstrom Macroglobulinemia 74 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 70 Sezary Syndrome 67 Lymphoma, Large-Cell, Immunoblastic 65 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 57 Lymphoma, Large-Cell, Anaplastic 54 Neoplasms, Plasma Cell 52 Myeloproliferative Disorders 52 Primary Myelofibrosis 46 Hematologic Neoplasms 44 Blast Crisis 43

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × rrCLL × Lymphoid × Clear all

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡